LINC01817

Across TCGA pan-cancer cohorts, LINC01817 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC01817’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where LINC01817 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01817 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

LUSC, LUAD, and LIHC are the cancer types where LINC01817 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01817 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	All	All	−0.078	<.001	5	view →
LUAD	All	II,III,IV	−0.099	.003	4	view →
LIHC	All	All	−0.028	.006	4	view →
PRAD	All	All	−0.045	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LINC01817–LUSC

Open the LUSC breakdown →